Antisense Therapeutics Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATHJF research report →
Companywww.antisense.com.au
Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial.
- CEO
- James Garner MBA
- IPO
- 2009
- HQ
- Toorak, VIC, AU
Price Chart
Valuation
- Market Cap
- $19.64M
- P/E
- -0.46
- P/S
- 0.00
- P/B
- 0.61
- EV/EBITDA
- -0.00
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -110.74%
- ROIC
- -137.13%
Growth & Income
- Revenue
- $2.97M · 87.88%
- Net Income
- $-11,919,223 · -4.74%
- EPS
- $-0.01 · 20.59%
- Op Income
- $-11,832,514
- FCF YoY
- -23.70%
Performance & Tape
- 52W High
- $0.07
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.02
- Beta
- 0.87
- Avg Volume
- 0
Get TickerSpark's AI analysis on ATHJF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ATHJF Coverage
We haven't published any research on ATHJF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ATHJF Report →